Spyre Therapeutics, Inc. (SYRE)
80.53
+0.42
(+0.52%)
USD |
NASDAQ |
Oct 07, 14:23
Spyre Therapeutics Net Income (Quarterly) : -36.20M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -36.20M |
| March 31, 2026 | -69.00M |
| December 31, 2025 | -51.83M |
| September 30, 2025 | -11.18M |
| June 30, 2025 | -36.72M |
| March 31, 2025 | -36.09M |
| December 31, 2024 | -43.67M |
| September 30, 2024 | -53.71M |
| June 30, 2024 | -26.75M |
| March 31, 2024 | -26.40M |
| December 31, 2023 | 180.73M |
| September 30, 2023 | -40.11M |
| June 30, 2023 | -217.08M |
| March 31, 2023 | -18.42M |
| December 31, 2022 | -18.82M |
| September 30, 2022 | -18.23M |
| June 30, 2022 | -22.32M |
| March 31, 2022 | -24.44M |
| December 31, 2021 | -20.45M |
| September 30, 2021 | -20.31M |
| June 30, 2021 | -6.83M |
| March 31, 2021 | -18.22M |
| December 31, 2020 | -22.71M |
| September 30, 2020 | -18.03M |
| Date | Value |
|---|---|
| June 30, 2020 | -21.42M |
| March 31, 2020 | -18.73M |
| December 31, 2019 | -21.50M |
| September 30, 2019 | -21.57M |
| June 30, 2019 | -18.02M |
| March 31, 2019 | -17.17M |
| December 31, 2018 | -14.90M |
| September 30, 2018 | -11.92M |
| June 30, 2018 | -9.414M |
| March 31, 2018 | -8.119M |
| December 31, 2017 | -6.483M |
| September 30, 2017 | -7.874M |
| June 30, 2017 | -6.632M |
| March 31, 2017 | -6.247M |
| December 31, 2016 | -5.483M |
| September 30, 2016 | -6.238M |
| June 30, 2016 | -5.43M |
| March 31, 2016 | -4.547M |
| December 31, 2015 | -3.987M |
| September 30, 2015 | -3.413M |
| June 30, 2015 | -1.427M |
| March 31, 2015 | -2.468M |
| December 31, 2014 | -3.181M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| Incyte Corp. | 585.60M |
| SELLAS Life Sciences Group, Inc. | -9.605M |
| Relay Therapeutics, Inc. | -83.71M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 36.20M |
| EPS Diluted (Quarterly) | -0.4272 |
| Enterprise Value | 6.056B |
| Earnings Yield | -2.71% |
| Normalized Earnings Yield | -2.796 |